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• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, 
has infected millions worldwide since its discovery in December 2019, but little is 
still known about the disease process. 
• Preliminary research in China notes liver function test (LFTs) abnormalities are 
common in COVID-19 patients, suggesting decreased hepatic function.
• Early data indicates abnormalities in LFTs are related to complicated disease 
course and negative outcomes.
• However, there has been limited large-scale data assessing COVID-19’s 
association with liver dysfunction and negative outcomes. 
• This study suggests that in COVID positive patients, those with elevated and super 
elevated LFTS have significantly higher odds of hospital admittance, ICU 
admittance, intubation, and death in comparison to those COVID-19 patients 
without elevated LFTs.
• As elevation in LFTs indicate hepatic damage or dysfunction, this research 
indicates that complicated COVID-19 pathogenesis has negative impact on hepatic 
function.
• While the link between LFTS elevation and poor outcomes in unknown, this finding 
is consistent with early data from other studies.
• LFT elevations may serve as an indicator for medical professional in the treatment 
of COVID-19 patients and may allow for proactive treatment of those patients at 
increased risk of complications.
• Of the 8,028 patients included in the study, 248 (3.1%) had a history of liver 
disease. Those with elevated/super elevated LFTs had significantly higher odds of 
having a history of liver disease (p<.001).
• We hypothesize that COVID-19’s negative impact on liver function exacerbates 
already lowered liver function in these patients, thus increasing their odds for 
complications
Discussion 
• 8,028 patients were included in the study (Table 1).  Binary indicator variables 
were created for having any elevated liver enzymes, defined as AST > 60, ALT > 
60, AP > 150, or bilirubin >1.5. Additionally, super elevated liver enzymes levels 
were defined as double the elevated threshold (AST and ALT > 120, AP > 300, 
bilirubin >3).
• Of the 8,028 patients, LFTs were available for interpretation in 3,937 patients 
(49%). (Table 2). 1,722 patients had elevated LFTS (45%). 714 patients had super 
elevated LFTS (19%)
• To examine the effects of elevated and super elevated liver enzymes on disease 
complications, a logistic regression model was performed. Presence of elevated 
and super elevated liver enzymes are associated with increased odds of liver 





The significance of this research is to investigate how COVID-19 affects the liver 
function and disease course in patients infected with the virus treated at Henry 
Ford Hospital from March to September 2020. 
Methods
• With IRB approval at Henry Ford Health System, medical records were analyzed to 
identify patients who test positive for COVID-19 from the start of the pandemic to 
September 2020.
• No individuals were excluded from the study
• Those with a medical history of liver dysfunction (i.e. cirrhosis, liver transplant, 
etc.) were isolated in a separate cohort.
• Records of all liver enzyme levels (AST, ALT, AP, bilirubin) and complicated 
disease process, defined as hospital admission, ICU admission, intubation, and 
death, were recorded.
Data Analysis
Continuous data are reported as Mean ± Standard Deviation; categorical data are 
reported as counts and column percentages (N (%)). Prevalence rates are 
computed using binary indicator variables. Logistic regression is used to calculate 
odds ratios and 95% confidence intervals. All analyses are performed using SAS 
9.4 (SAS Institute Inc., Cary, NC, USA).  
Conclusion 
Abnormal liver biochemistry is very common in COVID-19 patients, noted in 45% of 
our patient population. Those COVID-19 patients with abnormal LFTs are at a 



















Figure 1: Logistic regression for elevated and super elevated liver enzyme levels with 95% CI. 











Table 2: Hospital Outcomes and Elevated Liver Enzyme Prevalence Rates
Outcome Count (%) (95% CI) N=8028
History of liver disease 245 (3.1) (2.7, 3.5)
Death 673 (8.4) (7.8, 9.0)
Hospital admission 5199 (64.8) (63.7, 65.8)
Outcome Count (%) (95% CI) N=5199
ICU admit 807 (15.5) (14.6, 16.5)
Intubation 637 (12.3) (11.4, 13.2)
Outcome Count (%) (95% CI) 
Any elevated liver enzyme 1722 (44.9) (43.3, 46.5)
Elevated AST 1297 (33.5) (32.0, 35.0)
Elevated ALT 1052 (26.7) (25.4, 28.2)
Elevated AP 392 (10.1) (9.2, 11.1)
Elevated bilirubin 468 (12.0) (11.0, 13.1)
Any super elevated liver enzyme 714 (18.6) (17.4, 19.9)
Super elevated AST 480 (12.4) (11.4, 13.5)
Super elevated ALT 468 (11.9) (10.9, 13.0)
Super elevated AP 94 (2.4) (1.9, 3.0)
Table 1: Patient Demographics
Variable Response All Patients (N=8028)
Sex Female 4638 ( 58%)
Male 3389 ( 42%)
Unknown 1 (  0%)
Race Black 4268 ( 53%)
Other 1219 ( 15%)
White 2541 ( 32%)
Hispanic No 6921 ( 86%)
Unknown 768 ( 10%)
Yes 339 (  4%)
